Ken Griffin Calliditas Therapeutics Ab Transaction History

Citadel Advisors LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$20.04 - $25.66 $275,890 - $353,261	13,767 Added 1664.69%	14,594 $306,000
Q4 2023 Feb 14, 2024	SELL	$15.79 - $28.99 $65,228 - $119,757	-4,131 Reduced 83.32%	827 $21,000
Q3 2023 Nov 14, 2023	BUY	$15.68 - $20.38 $59,662 - $77,545	3,805 Added 330.01%	4,958 $90,000
Q2 2023 Aug 14, 2023	BUY	$15.7 - $25.61 $18,102 - $29,528	1,153 New	1,153 $18,000
Q4 2022 Feb 14, 2023	BUY	$11.5 - $19.6 $8,774 - $14,954	763 New	763 $12,000
Q1 2021 May 17, 2021	BUY	$27.01 - $32.92 $258,512 - $315,077	9,571 New	9,571 $264,000
Q3 2020 Nov 16, 2020	SELL	$21.61 - $25.69 $1.37 Million - $1.63 Million	-63,551 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$19.17 - $23.2 $1.22 Million - $1.47 Million	63,551 New	63,551 $1.48 Million

20.3K

Ticker CALT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 26,624,800
Market Cap $1.06B
Description
Calliditas Therapeutics AB (publ), a clinical-stage biopharmaceutical company, focused on identifying, developing, and commercializing pharmaceuticals products for treatments in orphan indications with initial focus on renal and hepatic diseases. It offers Nefecon, an oral formulation of budesonide that is an immunosuppressant for the treatment ...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.